Mereo BioPharma Group plc
MREO
$2.33
$0.031.30%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -46.79% | -51.43% | -8.91% | 40.29% | 34.37% |
| Total Depreciation and Amortization | 2.54% | 13.85% | 24.23% | 25.41% | 11.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.41% | 437.59% | 345.68% | 549.71% | 264.60% |
| Change in Net Operating Assets | 76.84% | -97.32% | 155.64% | -20.42% | 24.69% |
| Cash from Operations | -55.38% | -10.13% | 54.50% | 58.66% | 58.93% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -66.83% | -5,823.73% | -258.86% | -166.14% | -119.60% |
| Cash from Investing | -66.83% | -5,582.93% | -259.41% | -166.63% | -119.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -717.83% | -1,186.20% | -4,590.14% |
| Issuance of Common Stock | 305.00% | 305.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -92.12% | -86.38% | -914.73% | -548.03% | -352.85% |
| Cash from Financing | 478.79% | 459.92% | 8,930.22% | 2,145.28% | 4,908.17% |
| Foreign Exchange rate Adjustments | -108.27% | 151.10% | 104.68% | 112.74% | 122.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 215.05% | 173.47% | 164.18% | 80.81% | 82.56% |